Restoring Sensitivity to Immunotherapy Post Failure to the Pacific Regimen: a Pilot Study of Combined Durvalumab (MEDI 4736) and Grid Therapy for Non-Small Cell Lung Cancer
Latest Information Update: 09 Dec 2024
At a glance
- Drugs Durvalumab (Primary)
- Indications Brain metastases; Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Mayo Clinic
- 30 Jul 2024 Planned End Date changed from 30 Jun 2025 to 4 Aug 2030.
- 30 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 4 Aug 2025.
- 02 Jan 2024 The procedure of Biospecimen collection is added to treatment section.